Is GOVX or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Chemomab Therapeutics N/A -89.03% -79.68%

Do analysts prefer MAAQ or GOVX?

GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Mana Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, MAAQ or GOVX?

Mana Capital Acquisition has higher earnings, but lower revenue than GeoVax Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mana Capital Acquisition N/A N/A N/A N/A N/A GeoVax Labs $2.49M 1.64 -$21.47M -$19.12 N/A

Is MAAQ or GOVX more profitable?

Mana Capital Acquisition's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Mana Capital Acquisition N/A N/A N/A GeoVax Labs N/A -709.52% -399.33%

Do analysts recommend GOVX or QCLS?

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GOVX or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts recommend GOVX or AIMD?

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GOVX or AIMD?

Ainos has lower revenue, but higher earnings than GeoVax Labs. Ainos is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs $2.49M 1.64 -$21.47M -$19.12 N/A Ainos $120K 134.19 -$14.77M -$2.89 N/A

Is GOVX or AIMD more profitable?

GeoVax Labs has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Ainos -11,912.10% -160.55% -62.29%

Is GOVX or APLT more profitable?

Applied Therapeutics' return on equity of -340.84% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Applied Therapeutics N/A -340.84% -175.00%

GeoVax Labs (GOVX) Competitors

$1.18 +0.01 (+0.85%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$1.16 -0.02 (-1.69%)

As of 07/10/2026 07:47 PM Eastern

Compare

GOVX vs. CMMB, MAAQ, QCLS, AIMD, and APLT

Should you buy GeoVax Labs stock or one of its competitors? MarketBeat compares GeoVax Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeoVax Labs include Chemomab Therapeutics (CMMB), Mana Capital Acquisition (MAAQ), Mymd Pharmaceuticals (QCLS), Ainos (AIMD), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.

How does GeoVax Labs compare to Chemomab Therapeutics?

GeoVax Labs (NASDAQ:GOVX) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

GeoVax Labs has a beta of 3.68, indicating that its stock price is 268% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Chemomab Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.64	-$21.47M	-$19.12	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

In the previous week, Chemomab Therapeutics had 4 more articles in the media than GeoVax Labs. MarketBeat recorded 6 mentions for Chemomab Therapeutics and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 1.44 beat Chemomab Therapeutics' score of 0.61 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
Chemomab Therapeutics	Positive

GeoVax Labs currently has a consensus price target of $150.00, suggesting a potential upside of 12,611.86%. Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,336.78%. Given GeoVax Labs' higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics' return on equity of -89.03% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Summary

Chemomab Therapeutics beats GeoVax Labs on 9 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and GeoVax Labs (NASDAQ:GOVX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Mana Capital Acquisition's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
GeoVax Labs	N/A	-709.52%	-399.33%

GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Mana Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mana Capital Acquisition has higher earnings, but lower revenue than GeoVax Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
GeoVax Labs	$2.49M	1.64	-$21.47M	-$19.12	N/A

68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, GeoVax Labs had 2 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Mana Capital Acquisition. GeoVax Labs' average media sentiment score of 1.44 beat Mana Capital Acquisition's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
GeoVax Labs	Positive

Summary

GeoVax Labs beats Mana Capital Acquisition on 6 of the 9 factors compared between the two stocks.

How does GeoVax Labs compare to Mymd Pharmaceuticals?

GeoVax Labs (NASDAQ:GOVX) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GeoVax Labs had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for GeoVax Labs and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat GeoVax Labs' score of 1.44 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
GeoVax Labs	Positive
Mymd Pharmaceuticals	Very Positive

GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Mymd Pharmaceuticals' return on equity of -76.40% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Mymd Pharmaceuticals has lower revenue, but higher earnings than GeoVax Labs. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.64	-$21.47M	-$19.12	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

GeoVax Labs and Mymd Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to Ainos?

GeoVax Labs (NASDAQ:GOVX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

In the previous week, GeoVax Labs had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for GeoVax Labs and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat GeoVax Labs' score of 1.44 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
GeoVax Labs	Positive
Ainos	Very Positive

GeoVax Labs has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Ainos	-11,912.10%	-160.55%	-62.29%

Ainos has lower revenue, but higher earnings than GeoVax Labs. Ainos is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.64	-$21.47M	-$19.12	N/A
Ainos	$120K	134.19	-$14.77M	-$2.89	N/A

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 12,611.86%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market. Comparatively, Ainos has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

6.1% of GeoVax Labs shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 9.8% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GeoVax Labs and Ainos tied by winning 7 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to Applied Therapeutics?

GeoVax Labs (NASDAQ:GOVX) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

GeoVax Labs has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.64	-$21.47M	-$19.12	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

In the previous week, GeoVax Labs had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Applied Therapeutics. GeoVax Labs' average media sentiment score of 1.44 beat Applied Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
Applied Therapeutics	Neutral

Applied Therapeutics' return on equity of -340.84% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Applied Therapeutics	N/A	-340.84%	-175.00%

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

GeoVax Labs currently has a consensus price target of $150.00, suggesting a potential upside of 12,611.86%. Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given GeoVax Labs' higher probable upside, equities research analysts clearly believe GeoVax Labs is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Summary

Applied Therapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.10M	$3.76B	$7.13B	$12.64B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	N/A	21.83	27.42	24.58
Price / Sales	1.64	323.85	592.92	122.65
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	0.53	8.41	10.88	6.38
Net Income	-$21.47M	$23.85M	$3.59B	$331.87M
7 Day Performance	-0.84%	-0.75%	-0.26%	0.37%
1 Month Performance	N/A	8.81%	4.51%	0.53%
1 Year Performance	-93.01%	53.66%	29.17%	21.96%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	3.1842 of 5 stars	$1.18 +0.9%	$150.00 +12,611.9%	-92.9%	$4.10M	$2.49M	N/A	10	Short Interest Decrease
CMMB Chemomab Therapeutics	2.0499 of 5 stars	$2.40 +5.7%	$25.00 +941.7%	-62.5%	$16.34M	N/A	N/A	20	News Coverage High Trading Volume
MAAQ Mana Capital Acquisition	N/A	$1.99 -5.7%	N/A	-49.6%	$16.17M	N/A	N/A	1	Gap Up
QCLS Mymd Pharmaceuticals	0.7032 of 5 stars	$3.85 flat	N/A	N/A	$16.04M	N/A	N/A	6
AIMD Ainos	1.1096 of 5 stars	$2.04 +9.1%	N/A	-39.8%	$15.94M	$120K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. CMMB, MAAQ, QCLS, AIMD, and APLT

How does GeoVax Labs compare to Chemomab Therapeutics?

Summary

How does GeoVax Labs compare to Mana Capital Acquisition?

Summary

How does GeoVax Labs compare to Mymd Pharmaceuticals?

Summary

How does GeoVax Labs compare to Ainos?

Summary

How does GeoVax Labs compare to Applied Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. CMMB, MAAQ, QCLS, AIMD, and APLT

How does GeoVax Labs compare to Chemomab Therapeutics?

Which has more risk & volatility, GOVX or CMMB?

Do institutionals and insiders believe in GOVX or CMMB?

Which has higher earnings and valuation, GOVX or CMMB?

Does the media favor GOVX or CMMB?

Do analysts rate GOVX or CMMB?

Is GOVX or CMMB more profitable?

Summary

How does GeoVax Labs compare to Mana Capital Acquisition?

Is MAAQ or GOVX more profitable?

Do analysts prefer MAAQ or GOVX?

Which has stronger valuation & earnings, MAAQ or GOVX?

Do institutionals and insiders have more ownership in MAAQ or GOVX?

Does the media refer more to MAAQ or GOVX?

Summary

How does GeoVax Labs compare to Mymd Pharmaceuticals?

Do analysts recommend GOVX or QCLS?

Does the media favor GOVX or QCLS?

Which has more risk and volatility, GOVX or QCLS?

Is GOVX or QCLS more profitable?

Which has stronger valuation and earnings, GOVX or QCLS?

Do institutionals & insiders have more ownership in GOVX or QCLS?

Summary

How does GeoVax Labs compare to Ainos?

Does the media refer more to GOVX or AIMD?

Is GOVX or AIMD more profitable?

Which has better earnings & valuation, GOVX or AIMD?

Do analysts recommend GOVX or AIMD?

Which has more volatility and risk, GOVX or AIMD?

Do institutionals and insiders have more ownership in GOVX or AIMD?

Summary

How does GeoVax Labs compare to Applied Therapeutics?

Which has higher earnings and valuation, GOVX or APLT?

Does the media refer more to GOVX or APLT?

Is GOVX or APLT more profitable?

Do insiders and institutionals hold more shares of GOVX or APLT?

Do analysts recommend GOVX or APLT?

Which has more risk & volatility, GOVX or APLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools